Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP7 | P09237 | 4/20 | 0.33 |
| ▸ | MMP12 | P39900 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 4/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9634438 | 0.82 | TSHR (0.41) | TP53DNM1CA2CA1TSHR | |
| SCHEMBL1821175 | 0.78 | MMP1 (0.36) | TP53DNM1CA2CA1TSHR | |
| SCHEMBL10770770 | 0.77 | TP53 (0.46) | FAAHTP53CA2CA1FDPS | |
| SCHEMBL11046101 | 0.76 | TP53 (0.33) | TP53DNM1CA2CA1TSHR | |
| SCHEMBL28274457 | 0.73 | TP53 (0.43) | FAAHTP53CA2CA1FDPS | |
| SCHEMBL15825362 | 0.73 | TSHR (0.36) | FAAHTP53DNM1CA2CA1 | |
| SCHEMBL4132556 | 0.73 | — | — | |
| SCHEMBL21084338 | 0.72 | TP53 (0.37) | TP53DNM1CA2CA1TSHR | |
| SCHEMBL27289489 | 0.72 | TP53 (0.37) | TP53DNM1CA2CA1TSHR | |
| SCHEMBL6201439 | 0.72 | TP53 (0.46) | TP53DNM1CA2CA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | MCCARTHY JAMES R (US) | 2003-06-12 | — | — | US | disclosed |
| US-5977325-A | NUCLEOSIDE DERIVATIVES USEFUL AS ANTICARCINOGENIC/ANTITUMOR AGENTS AND VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5792841-A | ANTIVIRAL, ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5616702-A | ANTITUMOR AGENTS, VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5607925-A | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5378693-A | Antitumor agents or viricides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0372268-B1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMA (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0372268-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT14, NUDT1 | FAAH 4111/4885TP53 402/4885DNM1 3217/4885 |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT1, NUDT14 | FAAH 3997/4885TP53 450/4885DNM1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.